# C8 — 12-Week Execution Timeline: Full Detail

## Weeks 1-2: Foundation + Pipeline Build

**BUILD (O1):**
- [ ] CRM pipeline configured (S0-S6 stages + required fields) — **Jeff supports, CEO owns**
- [ ] Baseline documented: uptime, bugs, ship time, APM coverage — **Jeff**
- [ ] SonarQube Quality Gate enforced on deployments — **Jeff**
- [ ] APM instrumentation plan defined and started — **Jeff**
- [ ] Platform usage instrumentation plan created — **Charbel**
- [ ] BRA platform V1 demo-ability assessed (Y/N gate) — **Charbel**

**BUILD (O2):**
- [ ] Benchmark 10 therapeutic axes for business potential + platform fit — **Vassili**
- [ ] Select 2-3 therapeutic axes (2 main, 1 stretch) — **Vassili**
- [ ] Gap analysis started: Quality and use case per output — **Vassili**
- [ ] First KOL contacts scheduled for external validation — **Vassili**

**SELL:**
- [ ] Target account list: 50 accounts identified + researched — **CEO**
- [ ] Pricing sheet finalized (3 tiers + add-ons) — **CEO**
- [ ] 10 outbound emails sent to top targets — **CEO**
- [ ] 5 warm intro requests to investors/advisors — **CEO**
- [ ] 3 discovery meetings booked for Weeks 3-4 — **CEO**
- [ ] All existing pipeline reviewed + restaged — **CEO**
- [ ] Outbound email sequences drafted (cold, warm, re-engage) — **CEO**
- [ ] 2+ warm intros requested via Vassili's KOL network — **Vassili**

**INSTRUMENT:**
- [ ] Weekly OKR scoreboard live (B1 tables) — **All owners**
- [ ] Pipeline dashboard operational (B3) — **CEO + Jeff**
- [ ] Daily BRA OKR Scoreboard (30 min) cadence started — **All**
- [ ] Thursday "Fixing" session (60 min) cadence started — **Vassili + Charbel**
- [ ] Weekly cadence calendar invites sent (C1) — **CEO**

---

## Weeks 3-4: Pipeline Acceleration + First Demos

**BUILD (O1):**
- [ ] Epic 2 deployed in Production — **Charbel + Jeff**
- [ ] "Context" Alt. T. options at 50%+ completeness — **Data-Team + Vassili**
- [ ] Ship time improvements in progress — **Jeff**

**BUILD (O2):**
- [ ] Gap analysis + action plan completed for selected axes — **Vassili**
- [ ] Internal validation: test datasets generated — **Data-Team**
- [ ] One-pager per therapeutic area (sales collateral) — **CEO + Vassili**

**SELL:**
- [ ] 3-5 discovery calls completed — **CEO**
- [ ] 2-3 demos delivered — **CEO + Vassili**
- [ ] First pilot or proposal sent — **CEO**
- [ ] Pipeline reaches $500k+ qualified — **CEO**
- [ ] 5 additional warm intros received + converted to meetings — **CEO**
- [ ] Pilot proposal template (3 months, defined success criteria) — **CEO**
- [ ] Customer expansion proposal template — **CEO**

**VALIDATE:**
- [ ] BRA pipeline speed demonstrable in live demo? (Y/N) — **Charbel**
- [ ] Pilot success criteria template tested with 1 prospect — **CEO**
- [ ] Demo feedback collected from prospects — **CEO**

**INSTRUMENT:**
- [ ] Post-demo feedback form deployed — **Charbel**
- [ ] Pipeline coverage auto-tracking operational — **CEO**

---

## Weeks 5-6: Pipeline Peak + First Close Attempts

**BUILD (O1):**
- [ ] Epic 3 deployed in Production — **Charbel + Jeff**
- [ ] "Context" completeness at 75%+ — **Data-Team + Vassili**
- [ ] B&R Assessment F1 scores at 60%+ — **Data-Team**
- [ ] Platform availability at 97%+ — **Jeff**
- [ ] APM data at 50%+ coverage — **Jeff**

**BUILD (O2):**
- [ ] Dataset 1 structuring in progress — 50%+ complete — **Vassili + Data-Team**
- [ ] 2+ KOL interview sessions completed (external validation) — **Vassili**
- [ ] Reference story v1 (clinical outcome data for sales) — **Vassili + CEO**

**SELL:**
- [ ] Pipeline reaches $1.0M+ qualified — **CEO**
- [ ] 2-3 proposals outstanding — **CEO**
- [ ] First deal enters S5 (negotiation) — **CEO**
- [ ] First expansion conversation initiated — **CEO + Charbel**
- [ ] Target: $0-$100k ARR closed or in Commit forecast — **CEO**
- [ ] Sales deck v2 (incorporating Wk 3-4 demo feedback) — **CEO**
- [ ] "Why we win" competitive positioning document — **CEO**

**VALIDATE:**
- [ ] Deals progressing at expected pace? (check cycle time) — **CEO**
- [ ] If pipeline coverage <2x → CEO enters 100% pipeline mode — **CEO**

**INSTRUMENT:**
- [ ] Forecast model operational (Commit / Best Case / Upside) — **CEO**
- [ ] Win/loss tracking initiated — **CEO**

---

## Weeks 7-8: Closing Mode + Dataset Validation

**BUILD (O1):**
- [ ] Epic 4 deployed in Production — **Charbel + Jeff**
- [ ] "Context" at >= 90% completeness — KR1.2 target — **Data-Team + Vassili**
- [ ] B&R Assessment F1 at >= 85% — KR1.3 target — **Data-Team**
- [ ] Platform availability at 99%+ — KR1.5c target — **Jeff**
- [ ] 0 critical/major bugs in Prod — KR1.5b target — **Jeff**

**BUILD (O2):**
- [ ] Dataset 1 structured — KR2.1 first axis complete — **Vassili + Data-Team**
- [ ] External validation: 2+ outputs validated — **Vassili**
- [ ] LLM validation: test prompts created + validated — **Data-Team**
- [ ] GTM bundle for first therapeutic axis complete — **CEO + Vassili**
- [ ] Reference story v2 (quantified outcomes) — **CEO**

**SELL:**
- [ ] **First new logo closed ($100k-$175k)** — **CEO**
- [ ] Pipeline maintained at $1.2M+ (replenished) — **CEO**
- [ ] 2-3 additional deals at S4/S5 — **CEO**
- [ ] First expansion deal proposed — **CEO**

**VALIDATE:**
- [ ] Disease-specific demo used in live sales demo → customer reaction validated — **CEO + Vassili**
- [ ] Sales cycle data: tracking to <60 day average? — **CEO**

**INSTRUMENT:**
- [ ] Account health scores calculated for all active customers — **Charbel**
- [ ] Expansion trigger alerts configured — **Charbel + Jeff**

---

## Weeks 9-10: Acceleration + Second Wave Closes

**BUILD (O1):**
- [ ] Epic 5 deployed in Production — **Charbel + Jeff**
- [ ] Data Analysis V0 delivered — KR1.4 target — **Data-Team**
- [ ] Ship time at 10 min — KR1.5d target — **Jeff**
- [ ] APM data at 100% coverage — KR1.5e target — **Jeff**

**BUILD (O2):**
- [ ] Dataset 2 structured — KR2.1 target met (2 axes) — **Vassili + Data-Team**
- [ ] Internal validation: 4 outputs validated — KR2.2 target — **Data-Team**
- [ ] LLM validation: 4 outputs validated — KR2.2 target — **Data-Team**
- [ ] GTM bundle for second therapeutic axis complete — **CEO + Vassili**

**SELL:**
- [ ] **2nd and 3rd new logos closed** — **CEO**
- [ ] **First expansion deal closed** — **CEO**
- [ ] Pipeline: $1.5M+ (including next-quarter opps) — **CEO**
- [ ] Target: $350k-$400k ARR cumulative — **CEO**

**VALIDATE:**
- [ ] Repeatable sales motion: 2 deals followed same playbook? — **CEO**
- [ ] Disease-specific demo vs generic: faster close correlation? — **CEO**
- [ ] Expansion playbook tested on 1+ account — **CEO + Charbel**

**INSTRUMENT:**
- [ ] Next-quarter pipeline tracking initiated — **CEO**
- [ ] Sales velocity calculated (deal value x win rate x deals / cycle) — **CEO**

---

## Weeks 11-12: Close Sprint + Quarter Wrap

**BUILD (O1):**
- [ ] All 5 epics deployed — KR1.1a target met — **Charbel + Jeff**
- [ ] All KR1.5 reliability targets met — **Jeff**
- [ ] 10-50 users from 1-5 companies on platform — KR1.1b target — **App-Team + Sales-Team**

**BUILD (O2):**
- [ ] All datasets integrated in platform — KR2.3 at 100% — **Data-Team**
- [ ] 2 functional demos ready — KR2.3 target — **Data-Team + Vassili**
- [ ] All validation documentation finalized — **Vassili**
- [ ] All GTM materials finalized — **CEO + Vassili**

**SELL:**
- [ ] Every Commit deal pushed to signature — **CEO**
- [ ] Remaining expansion deals closed — **CEO**
- [ ] **Target: $500k ARR achieved** — **CEO**
- [ ] Next-quarter pipeline: $500k+ qualified — **CEO**

**VALIDATE:**
- [ ] Final quarter metrics compiled against all OKRs (O1 + O2 + O3) — **All owners**
- [ ] Sales motion documented: what worked, what repeats — **CEO**
- [ ] Disease-specific version vs generic deal comparison — **CEO**
- [ ] Quarter retrospective template — **CEO**
- [ ] Next-quarter OKR draft — **CEO + all**

**INSTRUMENT:**
- [ ] Full quarter dashboard finalized — **All owners**
- [ ] Board report: ARR + pipeline + unit economics + next-quarter plan — **CEO**

*Extracted from ArcaScience OKR Execution Blueprint — Part C*
